A Phase 4 interventional study of Secukinumab and nb-UVB in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 13 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-01-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 20th largest by enrollment, is one of 5 that started in 2017, is one of 17 in phase 4, and was the 35th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 25th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 in phase 4, and was the 45th registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).
This was and open label, parallel group, multicenter, randomized study with 3 clinical periods: Screening period, Treatment period, and Follow-up period.
The design consisted of the Main Study and a Mechanistic Sub study:
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the Main Study, 80 new-onset psoriasis patients in Arm A1 (68 in Arm A1a, 12 in Arm A1b) received 300 mg secukinumab injections weekly for the first month, then every 4 weeks until Week 48 (52-week treatment). Arm A1b patients also joined the Mechanistic Sub-study. In the Mechanistic Sub-study, 12 new-onset psoriasis patients (Arm A2) and 24 chronic plaque psoriasis patients (12 each in Arms C1 and C2) received similar secukinumab treatment. Arm A2 and C2 patients continued until Week 100 (104-week treatment), while Arm C1 ended at Week 48 (52-week treatment).
Biological: Secukinumab
In the Main Study, 80 new-onset psoriasis patients in Arm B1 (68 in Arm B1a and 12 in Arm B1b) received 1 or 2 cycles of nb UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 did not receive a second treatment cycle) (treatment duration = 52 weeks). Patients from Arm B1b participated also in the Mechanistic Sub-study.
Radiation: nb-UVB
Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.
Also known as: AIN457
Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52.
The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 52, relative to baseline PASI score.
Time frame: Baseline, Week 52
Number of Participants Who Achieved PASI 90 at Week 104
The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 104, relative to baseline PASI score.
Time frame: Baseline, Week 104
Number of Participants With IGA Mod 2011 0/1 Response at Week 52
Investigators assessed the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rated the disease from a score of 0 (clear skin) to 4 (severe disease). Response is defined as a score of 0 or 1 at Week 52.
Time frame: Baseline, Week 52
Subjects were enrolled in 2 study sites in Argentina, 4 in Bulgaria, 2 in Canada, 4 in Germany, 1 in Denmark, 3 in Estonia, 2 in Finland, 2 in Hungary, 6 in Poland, 8 in Spain, 2 in Sweden, 1 in Switzerland, and 4 in the United Kingdom.
| Milestone | Secukinumab 300 mg | Narrow-band Ultraviolet B (Nb-UVB) |
|---|---|---|
| Started | 116 | 80 |
| Modified full analysis set (mfas) | 77 | 76 |
| Subjects not treated | 3 | 4 |
| Main study | 80 | 80 |
| Mechanistic sub-study | 36 | 0 |
| Completed | 103 | 46 |
| Not completed | 13 | 34 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 6 |
| Withdrew: Lost to follow-up | 1 | 6 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Subject/guardian decision | 8 | 15 |
| Withdrew: Subjects not treated | 3 | 4 |
| Milestone | Secukinumab 300 mg | Narrow-band Ultraviolet B (Nb-UVB) |
|---|---|---|
| Started | 73 | 39 |
| Main study | 67 | 39 |
| Mechanistic sub-study | 6 | 0 |
| Completed | 13 | 8 |
| Not completed | 60 | 31 |
| Withdrew: Disease relapse | 32 | 7 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 4 | 6 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Study terminated by sponsor | 6 | 3 |
| Withdrew: Subject/guardian decision | 14 | 9 |
The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 52, relative to baseline PASI score.
| Participants | Secukinumab 300 mg A1 (A1a+A1b) | Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b) |
|---|---|---|
| Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52. | 70 | 32 |
The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 104, relative to baseline PASI score.
| Participants | Secukinumab 300 mg A1 (A1a+A1b) | Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b) |
|---|---|---|
| Number of Participants Who Achieved PASI 90 at Week 104 | 23 | 26 |
Investigators assessed the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rated the disease from a score of 0 (clear skin) to 4 (severe disease). Response is defined as a score of 0 or 1 at Week 52.
| Percentage of participants | Secukinumab 300 mg A1 (A1a+A1b) | Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b) |
|---|---|---|
| Number of Participants With IGA Mod 2011 0/1 Response at Week 52 | 85.7 (75.5 to 92.3) | 36.8 (26.3 to 48.7) |
Collected over On-treatment adverse events were collected from first dose of study treatment to 84 days after last dose of study medication (on-treatment), up to approximately 104 weeks. Evaluation of AEs and SAEs were repeated after dosing with study treatment (starting 85 days after last dose of treatment) until study termination notification.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg - On Treatment | 0/112 (0%) | 6/112 (5.4%) | 29/112 (25.9%) |
| Narrow-band Ultraviolet B (Nb-UVB) - On Treatment | 0/76 (0%) | 1/76 (1.3%) | 8/76 (10.5%) |
| Secukinumab 300 mg - Post Treatment Follow-up | 0/88 (0%) | 0/88 (0%) | 7/88 (8%) |
| Narrow-band Ultraviolet B (Nb-UVB) - Post Treatment Follow-up | 0/76 (0%) | 1/76 (1.3%) | 2/76 (2.6%) |
| Event | Secukinumab 300 mg - On Treatment | Narrow-band Ultraviolet B (Nb-UVB) - On Treatment | Secukinumab 300 mg - Post Treatment Follow-up | Narrow-band Ultraviolet B (Nb-UVB) - Post Treatment Follow-up |
|---|---|---|---|---|
| PancytopeniaBlood and lymphatic system disorders | 0/112 | 0/76 | 0/88 | 1/76 |
| Vocal cord polypRespiratory, thoracic and mediastinal disorders | 0/112 | 1/76 | 0/88 | 0/76 |
| Umbilical herniaGastrointestinal disorders | 1/112 | 0/76 | 0/88 | 0/76 |
| Ankle fractureInjury, poisoning and procedural complications | 1/112 | 0/76 | 0/88 | 0/76 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/112 | 0/76 | 0/88 | 0/76 |
| Tibia fractureInjury, poisoning and procedural complications | 1/112 | 0/76 | 0/88 | 0/76 |
| Acute stress disorderPsychiatric disorders | 1/112 | 0/76 | 0/88 | 0/76 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/112 | 0/76 | 0/88 | 0/76 |
| Event | Secukinumab 300 mg - On Treatment | Narrow-band Ultraviolet B (Nb-UVB) - On Treatment | Secukinumab 300 mg - Post Treatment Follow-up | Narrow-band Ultraviolet B (Nb-UVB) - Post Treatment Follow-up |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/112 | 5/76 | 3/88 | 1/76 |
| HeadacheNervous system disorders | 11/112 | 1/76 | 1/88 | 0/76 |
| Upper respiratory tract infectionInfections and infestations | 8/112 | 2/76 | 0/88 | 2/76 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/112 | 0/76 | 5/88 | 1/76 |
Subject disposition and baseline characteristics and presented using Randomized Set.
| Age, Customized(Participants) | Secukinumab 300 mg | Narrow-band Ultraviolet B (Nb-UVB) | Total |
|---|---|---|---|
| 18 to 30 years | 56 | 30 | 86 |
| 31 to 50 years | 60 | 50 | 110 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg | Narrow-band Ultraviolet B (Nb-UVB) | Total |
|---|---|---|---|
| Female | 35 | 25 | 60 |
| Male | 81 | 55 | 136 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 300 mg | Narrow-band Ultraviolet B (Nb-UVB) | Total |
|---|---|---|---|
| Black or African American | 1 | 1 | 2 |
| Asian | 2 | 3 | 5 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| White | 113 | 72 | 185 |
| Unknown | 0 | 1 | 1 |
| Other | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2017 to primary completion in Nov 2021, 56 months.
Results were first posted in Oct 2024, 2 years 10 months after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 56 months is above that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab